World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
44145
World Ranking
10687
National Ranking
5494

Robert S. Rosenson publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Robert S. Rosenson sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 606 publications — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Robert S. Rosenson D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Robert S. Rosenson sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 93 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Robert S. Rosenson is affiliated with the Icahn School of Medicine at Mount Sinai in the United States. Their research is primarily rooted in the field of Medicine, with a significant focus on Surgery, Cardiology and Cardiovascular Medicine, and Endocrinology, Diabetes and Metabolism. Additional areas of expertise include Economics and Econometrics as well as Cancer Research.

The scientist's work covers a range of topics, notably:

  • Lipoproteins and Cardiovascular Health
  • Lipid metabolism and disorders
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Cancer, Lipids, and Metabolism
  • Health Systems, Economic Evaluations, Quality of Life
  • Pharmaceutical Economics and Policy
  • Liver Disease Diagnosis and Treatment

The research is frequently published in notable venues including:

  • Journal of the American College of Cardiology
  • Circulation
  • Journal of clinical lipidology
  • Cardiovascular Drugs and Therapy
  • European Heart Journal

Frequent collaborators in their research include Paul Muntner, Daniel Gaudet, Lisandro D. Colantonio, Sascha N. Goonewardena, and Vera Bittner.

Among recent publications authored or co-authored by Robert S. Rosenson are:

  • Evinacumab for Homozygous Familial Hypercholesterolemia, 2020, New England Journal of Medicine
  • Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease, 2022, New England Journal of Medicine
  • Evinacumab in Patients with Refractory Hypercholesterolemia, 2020, New England Journal of Medicine
  • Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US, 2021, JAMA Cardiology
  • Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia, 2020, Journal of the American College of Cardiology

Best Publications

  • ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association

    Vallerie V. McLaughlin;Stephen L. Archer;David B. Badesch;Robyn J. Barst

  • Antiatherothrombotic Properties of Statins Implications for Cardiovascular Event Reduction

    Robert S. Rosenson;Christine C. Tangney

  • ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

    Vallerie V. McLaughlin;Stephen L. Archer;David B. Badesch;Robyn J. Barst

  • Cholesterol Efflux and Atheroprotection Advancing the Concept of Reverse Cholesterol Transport

    Robert S. Rosenson;H. Bryan Brewer;W. Sean Davidson;Zahi A. Fayad

  • ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents

    W. Gregory Hundley;David A. Bluemke;J. Paul Finn;Scott D. Flamm

  • Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.

    Scott M. Grundy;Gloria Lena Vega;Mark E. McGovern;Brian R. Tulloch

  • ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents

    Deepak L. Bhatt;James Scheiman;Neena S. Abraham;Elliott M. Antman

  • Dysfunctional HDL and atherosclerotic cardiovascular disease

    Robert S. Rosenson;H. Bryan Brewer;Benjamin J. Ansell;Philip Barter

  • Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance : The GAUSS-2 Randomized, Placebo-Controlled Phase 3 Clinical Trial of Evolocumab

    Erik Stroes;David Colquhoun;David Sullivan;Fernando Civeira

  • Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.

    P J Barter;C M Ballantyne;R Carmena;M Castro Cabezas

  • HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events

    Robert S. Rosenson;H. Bryan Brewer;M. John Chapman;Sergio Fazio

  • The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.

    Jean-Charles Fruchart;Frank Sacks;Michel P Hermans;Gerd Assmann

  • Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation

    Michael Pignone;Mark J. Alberts;John A. Colwell;Mary Cushman

  • Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial

    Steven E. Nissen;Erik Stroes;Ricardo E. Dent-Acosta;Robert S. Rosenson

  • Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women

    Samia Mora;James D. Otvos;Nader Rifai;Robert S. Rosenson

  • An assessment by the Statin Muscle Safety Task Force: 2014 update

    Robert S. Rosenson;Steven K. Baker;Terry A. Jacobson;Stephen L. Kopecky

  • Inhibition of proinflammatory cytokine production by pravastatin.

    Robert S Rosenson;Christine C Tangney;Larry C Casey

  • CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease Application to Clinical and Public Health Practice: Report From the Clinical Practice Discussion Group

    Sidney C. Smith;Jeffrey L. Anderson;Richard O. Cannon;Yazid Y. Fadl

  • Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes

    Michael Pignone;Mark J. Alberts;John A. Colwell;Mary Cushman

  • ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents.

    L. Kristin Newby;Robert L. Jesse;Joseph D. Babb;Robert H. Christenson

Frequent Co-Authors

Paul Muntner
Paul Muntner University of Alabama at Birmingham
Monika M. Safford
Monika M. Safford Cornell University
Vera Bittner
Vera Bittner University of Alabama at Birmingham
Deepak L. Bhatt
Deepak L. Bhatt Mount Sinai Hospital
Christie M. Ballantyne
Christie M. Ballantyne Baylor College of Medicine
Christopher P. Cannon
Christopher P. Cannon Brigham and Women's Hospital
James A. de Lemos
James A. de Lemos The University of Texas Southwestern Medical Center
Anna F. Dominiczak
Anna F. Dominiczak University of Glasgow
Mary Cushman
Mary Cushman University of Vermont
Kiran Musunuru
Kiran Musunuru University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always require following the traditional path of medical school. Many students and professionals are pursuing related online degrees that offer flexibility, faster completion times, and alternative roles in healthcare.

For those interested in nursing, accelerated programs like the 6 month lpn program provide a quick route to enter the nursing workforce. Similarly, those aiming for advanced practice can consider the shortest pmhnp program to become a Psychiatric-Mental Health Nurse Practitioner in less time.

If healthcare administration is your focus, online learning offers affordable options. Consider enrolling in the cheapest online healthcare administration degree for undergraduate studies or the cheapest mha programs online healthcare for graduate-level opportunities.

These pathways offer cost-effective alternatives and faster entry into vital healthcare roles, expanding your career prospects beyond the scope of a traditional medical degree.

Best Scientists Citing Robert S. Rosenson

Trending Scientists

Recently Published Articles